

## FORMULATION AND EVALUATION OF LIPOSOMES CONTAINING FAMOTIDINE

**Biresh K Sarkar<sup>\*1</sup>, Maddi Ramaiah<sup>2</sup>, Manish Devgan<sup>3</sup>, Y.Ankamma chowdary<sup>4</sup>**

<sup>1</sup>National Institute of Ayurvedic Pharmaceutical Research, Moti Bagh Road, Patiala, India.

<sup>2</sup>Department of Pharmacognosy, Hindu College of Pharmacy, Amaravathi Road Guntur, A.P,  
India.

<sup>3</sup>R.P. Educational Trust Group of Institutions Karnal, Haryana, India.

<sup>4</sup>NRI College of Pharmacy, Pothavarappadu, Krishna, A.P, India.

Article Received on  
16 May 2014,

Revised on 20 May 2014,  
Accepted on 04 July 2014

### \*Correspondence for

#### Author

**Biresh K Sarkar**

National Institute of Ayurvedic  
Pharmaceutical Research, Moti  
Bagh Road, Patiala, India.

### ABSTRACT

In the present study liposomal formulations containing Famotidine were prepared and studied. Liposomal formulations were evaluated for drug entrapment, surface characterization and *in-vitro* drug release studies. Drug excipient compatibility was determined by using spectral studies. Liposomal suspensions were prepared using film hydration technique by varying concentrations of ingredients and optimize the ideal combination for required drug release. The prepared liposomes were rigid, intact and fulfilled all official requirements. The results of *in vitro* drug release studies showed that release from liposomal formulation was slow and sustained for more than 8 hrs period. Thus

the liposomal suspensions of Famotidine were successfully formulated and established for their quality control parameters.

**KEY WORDS:** Liposome, Drug Release, Formulation, Famotidine.

### INTRODUCTION

Liposome defined as a spherical vesicle of lipid bilayers enclosing an aqueous compartment. Their size ranges from 25 to 5000 nm. The lipid most commonly used is phospholipids, sphingolipids, glycolipids and sterols. Liposomes may be formulated with a range of characteristics including different size, charge and drug retention, which can be tailored for a given drug and target site. They are used as a delivery system for drugs, genes and vaccines in therapeutics. Liposomes can also be actively targeted to specific cells or sub cellular

regions using targeting ligands attached to their surface or by modification of the bilayer to give triggered release under appropriate conditions [1-4].

Famotidine is a histamine H<sub>2</sub>-receptor antagonist. It is widely prescribed in gastric ulcers, duodenal ulcers, Zollinger-Ellison syndrome and gastro-esophageal reflux disease. In the management of benign gastric and duodenal ulceration the dose is 40 mg daily by mouth at bedtime, for 4 to 8 weeks. In the Zollinger-Ellison syndrome the initial dose by mouth is 20 mg every 6 hours, increased as necessary; dose up to 80 mg daily have been employed. The low bioavailability and short biological half life following oral administration of Famotidine motivate many researchers to improve its pharmacokinetics profile and many researchers made attempts in this direction like development of a sustained release formulation and utilization of other techniques which improve release profile of drug. [5, 6]

## MATERIAL AND METHODS

Famotidine was obtained as a gift sample in the form of crystalline powder. All other chemicals/reagents used were of analytical grade, available commercially and used as such without further processing.

## PREPARATION OF LIPOSOMES

Liposomes were prepared by thin film hydration technique. Accurately weighed quantities of phosphatidylcholine and cholesterol were dissolved in chloroform-ethanol mixture in different ratios in a round-bottomed flask. BHT, equivalent to 2% of the total lipids as an antioxidant, was added in the organic phase in the flask. The chloroform-ethanol mixture was evaporated by rotating the round bottom flask on the palms. After complete evaporation of organic solvents, hydration of the thin film was carried out. The various formulation variable considered in this research have been presented in **Table 1**.

**Table 1: Composition of lipids for preparation of liposome**

S. No	Formulation	Phosphatidylcholine (moles)	Cholesterol (moles)
1	L1	5.5	4.5
2	L2	6.5	3.5
3	L3	7.5	2.5
4	L4	8.5	1.5


## EVALUATIONS OF DIFFERENT PARAMETERS

### Estimation of Entrapped Drug


Drug entrapped within the liposomes was estimated after removing the untrapped drug, which was separated by collecting the supernatant after subjecting the dispersion to centrifugation in a cooling centrifuge at 1000 rpm the pellets of liposomes were washed again to remove any untrapped drug and the washing was combined with supernatant and was analyzed for drug content at 265 nm.

### Surface Characterization

The SEM studies for formulated liposomes were conducted and the pictures were shown in



**Fig. 1: SEM of liposomes**



**Fig. 2: Drug release profiles of formulations**

### ***In Vitro* drug release study**

The United States Pharmacopoeia basket-type dissolution rate test apparatus was used for all the *in vitro* release studies. A weighed quantity of the material was suspended in 900 mL of 0.1 mol HCL of pH 1.2. The dissolution medium was stirred at 100 rpm and maintained at constant temperature ( $37\pm 0.5^{\circ}\text{C}$ ). At present time intervals 5 mL aliquots were withdrawn and replaced by an equal volume of fresh pre-warmed dissolution medium maintaining sink condition throughout the experiment. After suitable dilution, the samples were analyzed for drug quantification at 265 nm using Double beam UV-VIS Spectrophotometer [7].

### **RESULTS AND DISCUSSION**

The liposomes formulation were prepared and evaluated for various characteristics; the result of IR spectral study shows characteristic peaks due to the pure Famotidine and peaks appeared in the spectra of Liposomes without any remarkable change in the position and comparable with standards. Liposomes with varying proportions as per shown in **Table 1** were prepared using hand shaking method. Drug entrapped efficiency were found to be from 77-89 % which indicates desirable consideration of drug dosing. The result of SEM studies for surface characterization reveals the uniform spherical size of liposomes with optimum ranges of size (**Figure 1**). Release profiles indicated that L4 showed 80%, L3 showed 73.2%, L2 showed 68.7%, L1 showed 62% for 8 hr of release study. Release of drug from all the formulated liposomes followed sustained release profile which was desirable to overcome the solubility problem of drug (**Figure 2**). All the prepared formulations follows diffusion controlled release mechanism. Hence release of Famotidine from the prepared liposomal formulation follows zero order kinetics by utilizing diffusion as a controlled release mechanism [8].

### **CONCLUSION**

The prepared liposomal formulations using different lipid cholesterol molar ratios were developed and evaluated. The evaluation studies concluded that higher the concentration of cholesterol rigidity of the bilayer will be more and showed better controlled release of drug. Hence the combination used in formulation were found to be optimum for achieving better controlled release thus the liposomal formulation of Famotidine would be a suitable means to produce more uniform release profile.

**REFERENCES**

1. G. Gregoriadis, Liposome technology: Liposome preparation and related techniques, 3<sup>rd</sup> Edn. Vol. 1, Informa Health care, New York, 21 (2007).
2. Friese J. In: Liposome Technology (Gregoriadis G., ed.) CRC Press, Florida, Vol.1, Chapter 10, p.131(1984).
3. New, R.R.C., Introduction and preparation of liposomes. In: New, R.R.C. (Ed.), Liposomes: A Practical Approach. Oxford University Press, Oxford, 1–104 (1990).
4. Lasic D D, Liposomes: from Physics to Applications. Elsevier, Amsterdam, London, NewYork. (1993).
5. Jain Abhishek Kumar, Jain C.P., Tanwar Y. S.and Naruka P.S., Formulation, Characterization and *In-Vitro* Evaluation of Floating Microspheres of Famotidine as a Gastro Retentive Dosage Form, Asian Journal of Pharmaceutics, 222-226, (2009).
6. Jaimini M., Rana A.C. and Tanwar Y.S., Formulation and Evaluation of Famotidine Floating Tablets, Current Drug Delivery, 4, 51-55 (2007).
7. Patel Asha, Ray Subhabrata and Thakur Ram Sharnagat, *In Vitro* Evaluation and Optimization of Controlled Release Floating Drug Delivery System of Metformin Hydrochloride, DARU, 14( 2), 57-64 (2006).
8. Cevc, G., Transferosomes, liposomes and other lipid suspensions on the skin permeation enhancement, vesicle penetration and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst, 13: 257-388 (1996).